Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial.
Neth Heart J
; 30(12): 567-571, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-36112340
ABSTRACT
BACKGROUND:
Although the short-term benefit of primary percutaneous coronary intervention (PCI) in elderly patients with ST-elevation myocardial infarction (STEMI) has been demonstrated, the final long-term survival benefit is as yet unknown.AIM:
To assess the final survival benefit of primary PCI as compared to thrombolytic therapy in patients over 75 years of age.METHODS:
Patients >â¯75 years with STEMI were randomised to either primary PCI or thrombolysis. Long-term data on survival were available for all patients.RESULTS:
A total of 46 patients were randomised to primary PCI, 41 to thrombolysis. There were no significant differences in baseline variables. After a maximum of 20 years' follow-up, all patients had passed away. The patients randomised to thrombolysis died after a mean follow-up duration of 5.2 years (SD 4.9) compared to 6.7 years (SD 4.8) in patients randomised to primary PCI (pâ¯= 0.15). Thus, the mean final survival benefit of primary PCI was 1.5 years.CONCLUSION:
The final survival benefit of primary PCI as compared to thrombolysis in elderly patients with STEMI is 1.5 years and their life expectancy increases by 28.8%.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Neth Heart J
Año:
2022
Tipo del documento:
Article
País de afiliación:
Países Bajos